CADM1: an Immunoglobulin Superfamily Molecule, a New Tumor Suppressor Gene!
CADM1: an Immunoglobulin Superfamily Molecule, a New Tumor Suppressor Gene!CADM1 is a cell adhesion molecule that belongs to the immunoglobulin superfamily, and it has a ubiquitous presence in the human body. Apart from its abundance in multiple normal tissues where it serves various functions,...
Detailed information

CD69: a Classical Early Marker of Lymphocyte Activation, a Pivotal Regulator of Hematologic Diseases and Autoimmune Disorders!
CD69: a Classical Early Marker of Lymphocyte Activation, a Pivotal Regulator of Hematologic Diseases and Autoimmune Disorders!A research paper entitled “HSF1 promotes CD69+Treg differentiation to inhibit colitis progression” was recently published in the journal Theranostics [1]. The study found that knockdown of CD69 induced autoimmune dis...
Detailed information

DSG2: a Vital Member of Desmosomal Cadherin Family, an Exciting New Target for Cardiomyopathy, Adenovirus, and Tumors!
DSG2: a Vital Member of Desmosomal Cadherin Family, an Exciting New Target for Cardiomyopathy, Adenovirus, and Tumors!DSG2 stands for desmoglein-2, which is a type of desmosomal cadherin protein. It is a well-established fact that mutations in a variety of desmogleins can lead to the development of cardiomyopathy, like Desmocollin-2, De...
Detailed information

ULBP1: a Potent Member of NKG2D Ligands in CAR-T Therapy for Multiple Hematological and Solid Tumors!
ULBP1: a Potent Member of NKG2D Ligands in CAR-T Therapy for Multiple Hematological and Solid Tumors!Lately, the world-leading haematology journal the Lancet Haematology published a report [1], suggesting that administering multiple infusions of CYAD-01 without preconditioning exhibited both favorable efficacy and safet...
Detailed information

IL-17A: A Major Cytokine of the IL-17 Family, a Key Inflammation Target in Skin Diseases, or Inflammation-Associated Cancers!
IL-17A: A Major Cytokine of the IL-17 Family, a Key Inflammation Target in Skin Diseases, or Inflammation-Associated Cancers!On March 25, 2023, China has achieved a significant milestone by successfully launching the first developed monoclonal antibody drug targeting IL-17A (Xeligekimab, GR1501). GR1501 is a human IL-17A-neutralizing IgG4 mono...
Detailed information

Analysis of Factors Influencing ELISA Detection
Analysis of Factors Influencing ELISA DetectionELISA is a mature detection technology, which has been widely applied since its origin in the 19th century due to its unparalleled advantages. To achieve accurate, perfect, and reproducible experimental results, experime...
Detailed information

Norwalk Virus
Norwalk VirusNorwalk virus, also known as Norovirus, is a common intestinal virus that can cause acute gastroenteritis. In recent years, Norwalk virus has become one of the main pathogens causing human gastrointestinal diseases, espe...
Detailed information

Cadherin-17 (CDH17): A Viable Target in Bispecific Antibodies or CAR-T Therapy to Fight Many Gastrointestinal Cancers!
Cadherin-17 (CDH17): A Viable Target in Bispecific Antibodies or CAR-T Therapy to Fight Many Gastrointestinal Cancers!Recently, CDH17 has rapidly gained attention as a promising target for gastrointestinal cancers. In 2025, two significant BD transactions have drawn widespread interest: in October, Hansoh Pharma licensed the ex-Greater ...
Detailed information

Exploring the Science of Influenza A Virus: What You Need to Know
Exploring the Science of Influenza A Virus: What You Need to KnowThe winter and spring seasons every year mark the peak period of influenza A virus outbreaks. Due to its numerous hosts in the natural environment and its high potential for mutation or recombination, each outbreak can c...
Detailed information

LY6G6D (LY6-G): A New Member of Lymphocyte Antigen-6 Family Holds Big Opportunities in Bispecific Antibody for CRC Treatment!
LY6G6D (LY6-G): A New Member of Lymphocyte Antigen-6 Family Holds Big Opportunities in Bispecific Antibody for CRC Treatment!Genentech, an innovative leader in large molecule pharmaceuticals, has developed a anti-LY6G6D/CD3 bispecific antibody (LY6G6D-TDB) for colorectal cancer (CRC) treatment in its earlier days. With an elaborately design, L...
Detailed information

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2025 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
×
20% OFF Promotion on CUSABIO Premium Active Proteins